KR20010097871A - Beverage composition for improving climacteric melancholia and nervous debility and method thereof - Google Patents
Beverage composition for improving climacteric melancholia and nervous debility and method thereof Download PDFInfo
- Publication number
- KR20010097871A KR20010097871A KR1020000022289A KR20000022289A KR20010097871A KR 20010097871 A KR20010097871 A KR 20010097871A KR 1020000022289 A KR1020000022289 A KR 1020000022289A KR 20000022289 A KR20000022289 A KR 20000022289A KR 20010097871 A KR20010097871 A KR 20010097871A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- depression
- beverage composition
- weights
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 235000013361 beverage Nutrition 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims description 7
- 208000020401 Depressive disease Diseases 0.000 title description 2
- 206010003549 asthenia Diseases 0.000 title 1
- 208000024714 major depressive disease Diseases 0.000 title 1
- 201000003995 melancholia Diseases 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 87
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 21
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960002442 glucosamine Drugs 0.000 claims abstract description 21
- 229940016409 methylsulfonylmethane Drugs 0.000 claims abstract description 21
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 21
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930091371 Fructose Natural products 0.000 claims abstract description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 10
- 239000005715 Fructose Substances 0.000 claims abstract description 10
- 235000013736 caramel Nutrition 0.000 claims abstract description 10
- 235000012907 honey Nutrition 0.000 claims abstract description 10
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 8
- 240000002045 Guettarda speciosa Species 0.000 claims abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 8
- 210000004207 dermis Anatomy 0.000 claims abstract description 8
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 7
- 229940069445 licorice extract Drugs 0.000 claims abstract description 7
- 229940002508 ginger extract Drugs 0.000 claims abstract description 6
- 235000020708 ginger extract Nutrition 0.000 claims abstract description 6
- 210000003056 antler Anatomy 0.000 claims abstract description 4
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 4
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 3
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 3
- 239000008513 turmeric extract Substances 0.000 claims abstract description 3
- 206010067371 Menopausal depression Diseases 0.000 claims description 25
- 229920001661 Chitosan Polymers 0.000 claims description 16
- 229920001542 oligosaccharide Polymers 0.000 claims description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 241000411851 herbal medicine Species 0.000 claims description 9
- 239000013505 freshwater Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims 2
- 239000011259 mixed solution Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 abstract description 31
- 230000003340 mental effect Effects 0.000 abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 abstract description 9
- 230000036506 anxiety Effects 0.000 abstract description 9
- 230000032683 aging Effects 0.000 abstract description 6
- 230000003925 brain function Effects 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 240000006079 Schisandra chinensis Species 0.000 abstract description 3
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000019116 sleep disease Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000020685 sleep-wake disease Diseases 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- 240000001879 Digitalis lutea Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 230000004596 appetite loss Effects 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000021266 loss of appetite Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010021654 increased appetite Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- DPHQKFPANOYYOP-BCOUGSAOSA-N CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DPHQKFPANOYYOP-BCOUGSAOSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001147791 Clostridium paraputrificum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000186568 Hathewaya limosa Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 241000193157 Paraclostridium bifermentans Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- -1 steroids saponins Chemical class 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Abstract
본 발명은 40대 후반의 폐경기 여성 또는 50대의 남성에게서 흔히 볼 수 있는 신경 쇠약과 정신적 불안정, 우울증 및 우울증에 따르는 수면장애, 불안초조등 뇌기능 저하에 따른 정신적, 신체적 노화를 개선하는 음료 조성물 및 그 제조방법에 관한 것이다. 본 발명의 음료 조성물은 2.0 내지 3.0중량의 녹용 추출액, 2.0 내지 3.0중량의 지황 추출액, 2.0 내지 3.0중량의 오미자 추출액, 8 내지 12중량의 당귀 추출액, 8 내지 12중량의 맥문동 추출액, 8 내지 12중량의 복령 추출액, 8 내지 12중량의 작약 추출액, 8 내지 12중량의 대추 추출액, 6 내지 10중량의 생강 추출액, 4 내지 8중량의 감초 추출액, 4 내지 8중량의 법제 산조인 추출액, 4 내지 8중량의 천궁 추출액, 4 내지 8중량의 진피 추출액, 2 내지 6중량의 치자 추출액, 2 내지 6중량의 꿀, 2 내지 6중량의 액상과당, 0.4 내지 0.8중량의 글루코사민, 0.4 내지 0.8중량의 메틸술포닐 메탄(MSM), 0.1 내지 0.3중량의 키토산올리고당, 및 0.1 내지 0.3중량의 카라멜을 포함한다.The present invention is a beverage composition that improves mental and physical aging due to the brain function, such as nervous breakdown and mental instability, depression and depression, depression anxiety, which is common in menopausal women in the late 40s or men in their 50s and It relates to a manufacturing method. The beverage composition of the present invention is 2.0 to 3.0 weight of antler extract, 2.0 to 3.0 weight of turmeric extract, 2.0 to 3.0 weight of Schisandra chinensis extract, 8 to 12 weight of Angelica extract, 8 to 12 weight of munmundong extract, 8 to 12 weight Bokryeong extract, 8-12 weight peony extract, 8-12 weight jujube extract, 6-10 weight ginger extract, 4-8 weight licorice extract, 4-8 weight legal Sanjo extract, 4-8 weight Cheongung extract, 4-8 weight dermis extract, 2-6 weight gardenia extract, 2-6 weight honey, 2-6 weight liquid fructose, 0.4-0.8 weight glucosamine, 0.4-0.8 weight methylsulfonyl methane (MSM), 0.1-0.3 weight of chitosan oligosaccharide, and 0.1-0.3 weight of caramel.
Description
본 발명은 신경 쇠약과 정신적 불안정, 우울증 및 우울증에 따르는 수면장애, 불안초조등 뇌기능 저하에 따른 정신적, 신체적 노화를 개선하는 음료 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a beverage composition for improving mental and physical aging due to a decrease in brain function such as nervous breakdown and mental instability, depression and depression, anxiety anxiety, and a method of manufacturing the same.
현대 사회가 점점 고도화되고 복잡해짐에 따라 사회생활 등에 따른 스트레스, 공업화에 따른 대기 공해의 증가, 환경오염에 따른 환경호르몬의 발현등 심각한 사회문제로 대두되어 지고 있고, 점차 나이가 들어감에 따른 여러 가지 질병의 발생은 신체적 노화의 자연적인 현상으로 받아들이고 있는 것이 오늘날의 현실이다. 특히, 40대 이후 점진적으로 진행(간혹, 20 ∼ 30대에 발명하기도 한다)하여 50대부터 발현하는 퇴행성관절염, 신경통, 우울중, 생활 습관성 질환, 우울증에 따르는 수면장애, 불안초조등 뇌기능 저하 등은 그 대표적인 예라 할 수 있다.As modern society becomes more advanced and complicated, it is becoming a serious social problem such as stress due to social life, increase of air pollution due to industrialization, and expression of environmental hormone due to environmental pollution. It is a reality today that the occurrence of disease is taken as a natural phenomenon of physical aging. In particular, progressive progression after the age of 40 (sometimes invented in 20-30), degenerative arthritis, neuralgia, depression, lifestyle disorders, depression, sleep disorders, depression anxiety, etc. And the like are representative examples.
우리의 감정과 생각은 뇌의 활동으로 생긴다. 뇌의 활동은 신경세포내에 있는 신경전달물질(시냅스 회로-뇌 신경말단에 저장되어 있다가 자극이 오면 신경 간극으로 분비되어 인접 신경 세포에 부착되어 신경 세포를 활동하게 하는 물질로 우울증과 관련되는 것은 세로토닌, 노르에프네프린 등이 있다.)을 통하여 이루어지는데 우울증, 정신적 불안 등은 이러한 뇌 전달물질의 기능이 잘못되어 생긴다고 생각하고 있다. 이러한 뇌 전달물질의 변화는 아무런 이유 없이도 우울증이 생기는 것으로 사료된다. 특히, 여성의 경우에는 20 내지 30대에 처음 발병하는 경우도 있으나, 나이가 들어 폐경기가 들어 월경이 더 이상하지 않게 되어 여성 호르몬의 급격한 감소에 의하여 초래되며, 남성의 경우는 퇴직한 후 사회적인 활동이 감소됨에 따라 일상 생활의 흥미나 즐거움이 없는 것을 원인으로 보는 사람도 적지 않다.Our emotions and thoughts come from brain activity. Brain activity is a neurotransmitter in nerve cells (synaptic circuits--stored in the nerve endings of the brain, and when stimulated, it is secreted into the nerve gap and attaches to adjacent nerve cells to activate nerve cells. Serotonin, norephnephrine, etc.), depression and mental anxiety are thought to be caused by the function of these brain transporters. These changes in brain transporters are thought to cause depression for no reason. In particular, in women in their 20s and 30s, the first onset, but the menopausal age is no longer menstruation is caused by a sharp decrease in female hormones, males are social activities after retirement As this decreases, there are not many people who see the cause of lack of interest or pleasure in daily life.
우울증의 약물학적 치료는 60 내지 70가 4주내에 증상 호전을 보이는 것으로 알려져 있으나, 가장 일반적인 증상인 수면장애가 수면효과를 지닌 약물 복용으로 인한 것으로 사료되며 약물적인 치료 및 정신, 심리학적 치료방법과 병행함으로써 큰 효과가 가능한 치료방법이나 예방방법이 한두 가지가 아니지만 확실한 예방과 호전을 기대할 수 있는 경우는 그리 많지 않다.Pharmacologic treatment of depression is known to improve symptoms within 60 to 70 weeks, but sleep disorder, the most common symptom, is thought to be caused by taking medication with sleep effect. By doing so, there are not one or two treatments or preventive methods that can make a big difference.
이러한 우울증은 대단히 흔한 질병이며 신체내에서 일어나는 생물학적인 반응을 충분히 이해하고 한방의 천연약재와 유효성분을 혼합하여 우울증의 근본적인 증세의 호전이 가능할 뿐만 아니라, 약물의 과다 복용 및 약물에 의한 부작용을 예방할 수 있고, 뇌 기능 강화에 의하여 우울증의 예방은 물론, 효과적으로 질환을 호전할 수 있고, 부수적으로 갱년기에 초래되는 우울증 및 긴경쇠약을 예방할 수 있는 천연 음료 조성물을 발견하여 예의 연구를 거듭한 결과, 본 발명을 완성할 수 있었다.This depression is a very common disease and it is possible to fully understand the biological reactions occurring in the body and to improve the fundamental symptoms of depression by mixing herbal medicines and active ingredients, as well as to prevent overdose and side effects caused by drugs. As a result of intensive research and finding a natural beverage composition that can prevent depression as well as effectively improve the disease by strengthening the brain function, and concomitantly prevent depression and prolonged weakness caused by menopause. The invention could be completed.
따라서, 본 발명의 목적은 우울증 및 신경쇠약의 개선에 아주 유용한 효능이 있는 음료 조성물을 제공하는데 있다.Accordingly, it is an object of the present invention to provide a beverage composition which is very useful for improving depression and nervous breakdown.
본 발명은 우울증 및 신경쇠약의 개선에 아주 유용한 효능이 있는 음료 조성물을 제공한다.The present invention provides a beverage composition which is very useful for improving depression and nervous breakdown.
본 발명은 천연약재와 우울증 및 신경쇠약에 효과가 있는 유효 성분을 혼합하여 함께 사용함으로써, 우울증 및 신경쇠약의 근본적인 증세를 호전시키고, 뇌기능 강화에 의해서 우울증 및 신경쇠약을 예방할 수 있는 음료 조성물을 제공하고 있다.The present invention by using a combination of natural ingredients and active ingredients effective in depression and nervous breakdown, by improving the fundamental symptoms of depression and nervous breakdown, drink composition that can prevent depression and nervous breakdown by enhancing brain function Providing.
상기 목적을 달성하기 위해서, 본 발명은 유효성분으로서 글루코사민, 메틸술포닐 메탄(MSM) 및 키토산올리고당과 한방의 천연약재를 함유하여, 우울증 및 신경쇠약 질병을 개선하는 음료 조성물을 제공하고 있다.In order to achieve the above object, the present invention contains a glucosamine, methylsulfonyl methane (MSM) and chitosan oligosaccharides and herbal natural herbs as an active ingredient, to provide a beverage composition for improving depression and nervous breakdown disease.
본 발명의 음료 조성물은 한방 약재와 0.4 내지 0.8중량의 글루코사민, 0.4 내지 0.8중량의 MSM, 및 0.1 내지 0.3 중량의 키토산올리고당을 함유한다.The beverage composition of the present invention contains herbal medicines, 0.4 to 0.8 weight of glucosamine, 0.4 to 0.8 weight of MSM, and 0.1 to 0.3 weight of chitosan oligosaccharides.
본 발명의 음료 조성물은 바람직하게 2.0 내지 3.0중량의 녹용 추출액, 2.0 내지 3.0중량의 지황 추출액, 2.0 내지 3.0중량의 오미자 추출액, 8 내지 12중량의 당귀 추출액, 8 내지 12중량의 맥문동 추출액, 8 내지 12중량의 복령 추출액, 8 내지 12중량의 작약 추출액, 8 내지 12중량의 대추 추출액, 6 내지 10중량의 생강 추출액, 4 내지 8중량의 감초 추출액, 4 내지 8중량의 법제 산조인 추출액, 4 내지 8중량의 천궁 추출액, 4 내지 8중량의 진피 추출액, 2 내지 6중량의 치자 추출액, 2 내지 6중량의 꿀, 2 내지 6중량의 과당, 0.4 내지 0.8중량의 글루코사민, 0.4 내지 0.8중량의 메틸술포닐 메탄(MSM), 0.1 내지 0.3중량의 키토산올리고당, 및 0.1 내지 0.3중량의 카라멜을 포함한다.The beverage composition of the present invention is preferably 2.0 to 3.0 weight of antler extract, 2.0 to 3.0 weight of turmeric extract, 2.0 to 3.0 weight of Schisandra chinensis extract, 8 to 12 weight of Angelica extract, 8 to 12 weight of munmundong extract, 8 to 12 weights of Fuling extract, 8-12 weight peony extract, 8-12 weight jujube extract, 6-10 weight ginger extract, 4-8 weight licorice extract, 4-8 weight legal Sanjo extract, 4-8 Heavy saline extract, 4-8 weight dermis extract, 2-6 weight gardenia extract, 2-6 weight honey, 2-6 weight fructose, 0.4-0.8 weight glucosamine, 0.4-0.8 weight methylsulfonyl Methane (MSM), 0.1 to 0.3 weight of chitosan oligosaccharide, and 0.1 to 0.3 weight of caramel.
한편, 상기한 본 발명의 갱년기 우울증 및 신경쇠약 개선 음료 조성에 있어서, 각 구성성분의 첨가량이 전술한 첨가량 보다 적은 경우에는 바람직한 갱년기 우울증 및 신경쇠약 개선 효과가 나타나지 않았으며 전술한 첨가량 보다 많은 경우에는 첨가량에 비례하여 갱년기 우울증 및 신경쇠약 개선 효과가 크게 상승하지 않으며 제조 원가의 상승을 초래하여 경제성이 떨어진다.On the other hand, in the above-mentioned menopausal depression and nervous breakdown beverage composition of the present invention, when the addition amount of each component is less than the above-mentioned addition amount did not show the effect of improving the menopausal depression and nervous breakdown, and in the case of more than the above-mentioned addition amount In proportion to the amount added, the effect of improving menopausal depression and nervous breakdown does not increase significantly, resulting in an increase in manufacturing cost, resulting in low economic efficiency.
상기한 본 발명의 목적을 달성하기 위한 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물의 제조 방법은 천연 한약재를 엄격히 선별하여 청수를 가한 후에 90 내지 97℃에서 6 내지 10시간 동안 추출하여 여과한 후 추출원액을 얻는 단계, 상기 추출원액에 글루코사민, MSM, 키토산올리고당을 80 내지 90℃에서 혼합한 후 꿀과 과당, 및 카라멜을 혼합하는 단계, 상기 혼합액을 90 내지 100℃에서 15 내지 30초 고온 살균처리하여 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 수득하는 단계를 포함한다.The method for producing a menopausal depression and nervous breakdown improvement natural beverage composition for achieving the above object of the present invention is strictly selected natural herbal medicines after adding fresh water and then extracted and filtered for 6 to 10 hours at 90 to 97 ℃ extract extract To obtain the step, the glucosamine, MSM, chitosan oligosaccharides are mixed in the extract stock at 80 to 90 ℃ mixed with honey and fructose, and caramel, the mixture is hot sterilized 15 to 30 seconds at 90 to 100 ℃ Obtaining a menopausal depression and nervous breakdown natural beverage composition.
이때, 상기한 본 발명의 방법은 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 캔에 충진하여 120 내지 125℃에서 15 내지 18분간 고압 살균하는 단계, 또는 레토르트파우치 또는 이와 유사한 소정용기에 충진하여 60 내지 95℃에서 30 내지 15분간 후살균하는 단계를 추가로 포함할 수 있다.At this time, the method of the present invention is a step of filling the can with a menopausal depression and nervous breakdown natural beverage composition to autoclave at 120 to 125 ℃ for 15 to 18 minutes, or a retort pouch or a similar container 60 to 60 to fill It may further comprise the step of post-sterilization at 95 ℃ 30 to 15 minutes.
본 발명의 음료 조성물에 함유되는 유효성분의 효능은 다음과 같다.The efficacy of the active ingredient contained in the beverage composition of the present invention is as follows.
글루코사민Glucosamine
포도당에 클루타민이라는 아미노산으로 구성된 물질로 연골, 피부, 손톱, 머리카락을 비롯한 신체 조직구조를 이루는 중요한 성분이다.It is a substance composed of amino acid called glutamine in glucose and is an important component of body tissue including cartilage, skin, nail and hair.
천연 아미노당의 일종인 글루코사민은 염의 형태로 유럽 등에서 변형성관절염의 치료약으로 사용되고 있으며, 또한, 미국에서는 5∼6년 전부터 영양 보조식품으로 판매되어 큰 시장을 형성하고 있다. 또한, 일본에서는 이미 오래전부터 식품 첨가물로 등재되어 사용되고 있으며, 관절을 혹사하는 운동선수, 노인, 노약자, 관절염을 앓고 있는 환자 등에 여러 식품 소재로써 일본 건강??영양식품협회에 의하여 규격기준을 작성하는 실정이다. 글루코사민은 당단백질, 당지질 및 뮤코다당체등의 중요한 생체성분으로서 널리 분포되어 있는 대표적인 천연아미노당이다.Glucosamine, a type of natural amino sugar, is used in Europe as a salt for treating osteoarthritis. In the United States, Glucosamine has been marketed as a nutritional supplement for five to six years. In addition, Japan has been listed as a food additive for a long time, and standards for the athletes, senior citizens, the elderly, the elderly, and patients suffering from arthritis have been prepared by the Japan Health and Nutrition Association. It is true. Glucosamine is a representative natural amino sugar widely distributed as important biological components such as glycoproteins, glycolipids, and mucopolysaccharides.
글루코사민은 생체중의 여러 가지 복합 당질의 당쇄중에 구성단위로 존재한다. 그 대표적인 것이 콘드로이친황산이나 히아론산의 뮤코다당류를 포함하는 프로테오글리칸이며, 종합조직, 피부조직, 연골 및 관절액등에 많이 분포되어 있다. 이들은 높은 보습효과를 가지고 세포의 기능이나 형태를 유지하며 윤활작용, 세포접착, 증식, 분화 등의 세포표면에 있어서 중요한 기능을 담당하고 있다.Glucosamine exists as a structural unit in the sugar chains of various complex saccharides in vivo. The most representative of these is proteoglycans containing mucopolysaccharides of chondroitin sulfate and hyaluronic acid, and are widely distributed in comprehensive tissues, skin tissues, cartilage and joint fluids. They have high moisturizing effect, maintain cell function and shape, and play important functions in cell surface such as lubrication, cell adhesion, proliferation and differentiation.
글루코사민은 모유중의 올리고당이 구성단위이며, 비피더스균의 증식인자로 작용한다. 각종 장내세균에 의한 기질 이용성을 글루코스, 락토오스와 비교하여 나타내었는데(표 1), 글루코사민은 장내 세균에 의한 기질로서 이용되기가 어려우므로 소화액의 분비로 pH의 저하 때문에 장내에서 유익한 균인 비피더스균의 증식을 돕고 반대로 유해한 균의 증식을 억제하므로 장내 미생물의 균총을 변화시켜 영양분의 흡수를 돕고 유해성분의 체내 배출 및 적당한 수분의 유지로 정상적인 변으로 변화시켜주므로 변비 개선효과 등 많은 유익효과를 부여한다.Glucosamine is composed of oligosaccharides in breast milk and acts as a growth factor for bifidus bacteria. The use of substrates by various intestinal bacteria was compared with glucose and lactose (Table 1). Since glucosamine is difficult to be used as a substrate by intestinal bacteria, the growth of bifidobacteria, a beneficial bacterium in the intestine, is due to the decrease in pH due to the secretion of digestive fluids. In contrast, by inhibiting the growth of harmful bacteria, by changing the flora of the intestinal microflora, it aids the absorption of nutrients and changes the normal stool by releasing harmful substances in the body and maintaining proper moisture, thereby giving many beneficial effects such as constipation improvement.
또한, 글루코사민염의 변형성관절염(퇴행성관절염)에 대한 치료효과에 대하여 많은 연구가 진행되었다. 변형성관절염 환자 30명을 2군으로 나누고 시험군에는 글루코사민황산염을 400mg/l 일씩 7일간 주사에 의해 투여하고 그 후 2 주간 1.5g/l일씩 경구 투여하였다(대조군은 관절염 치료제를 동량 사용하였다). 그 결과, 주사투여기간중에는 대조군과 함께 개선되었지만, 시험군에서 특히 관절의 회복이 현저하였다. 기능투여 기간에도 시험군이 증상의 개선이 현저하였으나, 대조군은 치료전의 상태로 되돌아갔다. 개선되었지만, 시험군에서 특히 관절의 회복이 현저하였다. 기능 투여기간에도 시험군이 증상의 개선이 현저하였으나, 대조군은 치료전의 상태로 되돌아갔다. 글루코사민의 투여는 부작용이 없는 변형성관절염의 치료제로서 적합하였다.In addition, many studies have been conducted on the therapeutic effect of glucosamine salts for degenerative arthritis (degenerative arthritis). Thirty patients with osteoarthritis were divided into two groups, and the test group was administered glucosamine sulfate by injection for 7 days at 400 mg / l for 7 days and then orally at 1.5 g / l for 2 weeks (the control group used the same amount of the arthritis treatment agent). As a result, it improved with the control group during the injection period, but the recovery of the joint was remarkable especially in the test group. In the administration period, the test group showed significant improvement of symptoms, but the control group returned to the state before treatment. Although improved, the recovery of joints was particularly pronounced in the test group. In the period of functional administration, the test group showed significant improvement of symptoms, but the control group returned to the state before treatment. Administration of glucosamine was suitable as a therapeutic agent for osteoarthritis with no side effects.
메틸 술포닐 메탄(MSM)Methyl Sulfonyl Methane (MSM)
MSM을 이해하기 위해서는 생물학적 유황의 인체에 미치는 기능에 대하여 이해하여야 한다. 생물학적 유황은 인체에 있어서 매우 중요한 미네랄이다. 이것은 황함유 아미노산(메티오닌, 시스테인, 시스틴)의 구성물질이며, 타우린, 글루타치온 등의 화학구조의 일부를 이루는 산-형성 아미노산이다. 생물학적 유황이 우리인체에서의 중요한 기능은 항균작용, 비만 및 알레르기의 해독제로 널리 사용되며, 산화작용을 돕고 심장운동을 정상화시키고, 순환을 향상시키며, 혈액에서의 유산소 매체로서 작용한다. 또한, 신체 노화작용을 느리게 하고 삶을 연장시킨다. 이런 생물학적 유황의 부족은 심리적인 스트레스, 육체적 피로감의 축적 그리고 기관과 세포의 악기능 뿐만 아니라 피곤과 질병에 대한 저항성이 떨어진다. 더욱이, 손톱이나 머리카락의 성장부족과 더불어 피부염이나 비만, 알레르기, 변비 등의 신체적인 불균형 상태를 유발시킨다.To understand MSM, it is necessary to understand the function of biological sulfur on the human body. Biological sulfur is a very important mineral for the human body. It is a constituent of sulfur-containing amino acids (methionine, cysteine, cystine) and is an acid-forming amino acid that forms part of the chemical structure of taurine, glutathione and the like. Biological sulfur is widely used as an antidote for antibacterial activity, obesity and allergy in human body, and it helps to oxidize, normalize cardiovascular exercise, improve circulation, and act as aerobic medium in blood. It also slows body aging and prolongs life. This lack of biological sulfur is less resistant to fatigue and disease, as well as psychological stress, accumulation of physical fatigue and bad function of organs and cells. In addition, lack of growth of nails and hair, as well as physical imbalances such as dermatitis, obesity, allergies, constipation.
MSM은 모든 형태의 관절염, 근육경련, 감염성 기생충을 포함하는 스트레스나 속쓰림, 알레르기 반응, 약물 과민성, 점막의 염증, 순환계질환, 염증질환 등을 포함한 심리적인 증상을 정상화시키는데 도움을 준다. 뿐만 아니라, 비타민 C의 전구체이며 근육조직의 효과적인 에너지원 보조제로서 사용되기도 한다.MSM helps to normalize psychological symptoms, including all forms of arthritis, muscle spasms, infectious parasites, including stress or heartburn, allergic reactions, drug hypersensitivity, mucosal inflammation, circulatory diseases, and inflammatory diseases. In addition, it is a precursor of vitamin C and used as an effective energy source supplement for muscle tissue.
MSM의 다른 효과를 언급하지 않더라도 이러한 것만으로도 사람의 에너지 수준은 증가되고 오랫동안 유지될 수 있다. 또한, 적당한 양의 MSM은 세포근육조직내에서 젖산 생성을 소멸시켜주는 것을 도와주며, 세포벽의 유연성을 회복시키는데 도움을 준다.Even without mentioning other effects of MSM, this alone can increase human energy levels and sustain them for a long time. In addition, the appropriate amount of MSM helps to eliminate lactic acid production in cell muscle tissue and to restore cell wall flexibility.
키토산올리고당Chitosan oligosaccharide
키틴, 키토산은 천연 다당류로서 최근에 그 생리적 기능이 우수하여 주목받고 있는 기능성 소재이다. 키틴은 게, 새우 등의 갑각류 껍질 부분에 함유되어 있으며 보통 용매에 불용성이므로 그 용도가 매우 한정되어 대부분 키토산의 원료로 사용되고 있으며, 키토산은 키틴을 강알카리로 탈아세틸화하여 제조하고 있다.Chitin and chitosan are natural polysaccharides, which are recently attracting attention due to their excellent physiological functions. Chitin is contained in crustacean shells such as crabs and shrimps, and is generally insoluble in solvents, so its use is very limited, and it is mostly used as a raw material for chitosan. Chitosan is prepared by deacetylating chitin with strong alkali.
최근, 키틴, 키토산 및 그 올리고당의 유도체가 면역증강 및 항암작용, 콜레스테롤 개선 및 고혈압 억제작용 등의 여러 가지 우수한 생리활성을 가지고 있음이 밝혀짐으로써 생리기능성 신소재로 개발되고 있다. 이러한 키토산은 분자량이 매우 크고 용해도가 낮아 우수한 생리활성을 가지고 있음에도 불구하고 그 응용의 폭이 제한되고 있으나, 키토산올리고당은 이러한 문제점을 해결하여 키토산의 생리활성을 가지면서 체내 흡수율을 증가시켰다.Recently, chitin, chitosan and its oligosaccharide derivatives have been developed as a new physiologically functional material, as it has been found to have various excellent physiological activities such as immune enhancement and anticancer activity, cholesterol improvement and hypertension suppression. Although chitosan has a very high molecular weight and low solubility and has excellent physiological activity, its application is limited, but chitosan oligosaccharides have solved this problem and have increased physiological activity of chitosan while increasing the absorption in the body.
본 발명의 음료 조성물에 함유되는 키토산올리고당은 면역력 증가작용, 혈당상승억제작용, 콜레스테롤 조정작용, 발암물질 및 방사능물질의 체내 배출작용, 유해중금속 체내 배출작용, 및 체내 유익균의 증식작용을 나타낸다.Chitosan oligosaccharides contained in the beverage composition of the present invention exhibits an increase in immunity, an effect on suppressing blood sugar elevation, cholesterol regulation, release of carcinogens and radioactive substances, release of harmful heavy metals, and proliferation of beneficial bacteria in the body.
또한, 본 발명의 음료 조성물에 함유되는 한약재 추출물은 한약재를 청수에 가하고 97℃에서 8시간 동안 가열한 후에, 여과함으로써 얻을 수 있으며, 한약재 각각의 효능은 다음과 같다.In addition, the herbal extract contained in the beverage composition of the present invention can be obtained by adding the herbal medicine to fresh water and heated at 97 ° C. for 8 hours, followed by filtration, and the efficacy of each herbal medicine is as follows.
녹용은 간 기능 강화 및 신경 안정작용, 성 기능 강화, 피로회복, 강장·강정작용, 근육과 뼈의 강화, 및 중추신경 흥분작용을 나타낸다.Deer antler has liver function enhancement and nerve stabilization, sexual function enhancement, fatigue recovery, tonic and gangjeong action, muscle and bone strengthening, and central nervous excitability.
감초는 청열 해독작용, 완급정통작용, 약성 조화등 약물중독에 대한 해독작용이 있다.Licorice has a detoxifying effect on drug addiction, such as detoxification, thorough orthodoxy, and drug harmony.
지황은 쇠약한 심장에 대하여 현저한 흥분효과 및 비교적 안정화 효과를 나타낸다.Rehmannia chinensis has a pronounced excitatory and relatively stabilizing effect on a weak heart.
복령은 신경쇠약 및 신경안정작용을 하며, 비타민류가 풍부하여 질병에 대한 저항력을 증강시키고 체내 전해질의 배출을 촉진하여 진정작용과 혈압강하작용을 한다.Fukryeong has a nervous breakdown and nerve stabilizing action, rich in vitamins to increase the resistance to disease and promote the discharge of electrolytes in the body to act sedation and blood pressure lowering.
산조인(법제)은 심과 담, 간을 보하고, 진정작용, 진통작용, 최면작용 등 신경쇠약에 효능이 있다.Sanjoin (legislation) is good for the nervous breakdown, heart and phlegm, liver, sedation, analgesic, hypnotic action.
오미자는 심혈관 기능을 조절하여 혈액 순환장애를 효과적으로 개선시키고 대뇌 피질의 기능을 향상시키며 호흡 및 중추 흥분작용을 돕는다.Schisandra chinensis regulates cardiovascular function, effectively improving blood circulation disorders, improving cerebral cortex function, and helping breathing and central excitability.
천궁은 대뇌 활동을 억제하고 연수의 호흡중추와 혈관 운동 중추를 흥분시키고 말초 혈관을 직접 확장시키고 관상동맥의 혈류량을 증가시켜 심근의 급성허혈성산소 결핍상태를 개선시킨다.The uterus improves myocardial acute ischemic oxygen deficiency by inhibiting cerebral activity, exciting the respiratory and vascular motor centers of the training, direct dilation of peripheral blood vessels, and increased blood flow in the coronary arteries.
치자는 열병에 의한 번뇌, 우울증에 사용되며, 피로회복, 건위, 정장효과가 크다.Gardenia is used for fever, depression, and fatigue.
작약은 신경통 류머티스 관절염 및 신경쇠약등에 사용되는데, 페놀성분이 진정, 해열, 진통작용에 사용된다.Peony is used for neuralgia rheumatoid arthritis and nervous breakdown, and phenol is used for soothing, antipyretic and analgesic action.
당귀는 피로회복, 식용증진, 강정에 효과가 탁월하며, 관상동맥의 혈류량을 증가시켜 피투이트린(Pituitrin)에 의하여 생기는 심근허혈을 예방하는데 효과가 크다.Angelica excels in fatigue recovery, food intake, and strengthening, and increases the blood flow in the coronary arteries and is effective in preventing myocardial ischemia caused by Pituitrin.
맥문동은 아스파라긴, 콜린, 알기닌, 여러 가지 스테로이드 사포닌, 비타민 등을 함유하여 강장,피로회복, 식욕증진, 정신안정에 효과가 있다.Macmundong contains asparagine, choline, arginine, various steroids saponins, vitamins, etc. It is effective in tonic, fatigue, appetite and mental stability.
대추는 간장을 보하고 근육의 힘을 증강시키며, 항과민성 작용을 한다.Jujube protects the liver, strengthens muscle strength, and has anti-hypersensitivity effects.
생강은 정유성분이 혈액 순환을 촉진하고 방향건위제로 진통, 해소, 복통등 해소 생강 고유 성분인 깅게롤(Gingerol)은 위액분비 및 연동작용을 촉진하여 소화를 돕는다.Gingerol essential oils to promote blood circulation and relieve pain, relieve pain, abdominal pain, etc. Gingerol, a unique ingredient of ginger, promotes gastric juice secretion and peristalsis to help digestion.
진피는 심혈관계의 흥분작용이 있다.The dermis is the excitement of the cardiovascular system.
본 발명의 갱년기 우울증 및 신경쇠약 개선 음료 조성물은 하루에 100 내지 160ml(g)의 양으로 음용할 수 있으며, 바람직하게는 식전 1시간 내지 1 시간 30분전과 취침 1시간 내지 1시간 30분전 일일 2회씩 매회 50 내지 80ml(g)의 양으로 음용할 수 있다.The menopausal depression and nervous breakdown improving beverage composition of the present invention can be drinkable in an amount of 100 to 160ml (g) per day, preferably 1 hour to 1 hour 30 minutes before meals and 1 hour to 1 hour 30 minutes before bedtime 2 It can be drunk in an amount of 50 to 80 ml (g) each time.
본 발명의 음료 조성물은 40대 후반의 폐경기 여성 또는 50대 남성에게서 흔히 볼 수 있는 신경쇠약과 정신적 불안정, 우울증 및 우울증에 따르는 수면장애, 불안초조등 뇌기능 저하에 따른 정신적, 신체적 노화를 개선하는 효과가 있다.The beverage composition of the present invention improves the mental and physical aging due to the brain function, such as nervous breakdown and mental instability, depression and depression, anxiety anxiety, commonly seen in postmenopausal women or men in their 50s. It works.
실시예 1Example 1
천연 한약재를 엄격히 선별하여 청수를 가한 후 97℃에서 8시간 동안 추출하여 여과한 후 추출원액을 얻었다. 추출원액에 글루코사민, MSM, 키토산올리고당을 85℃에서 혼합한 후 꿀과 과당, 그리고 카라멜을 혼합하여 균질화한 후 혼합액을 95℃로 보정된 HTST(고온 살균기)에서 15초 고온 살균처리하여 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 제조하였다.Natural herbal medicines were strictly selected, fresh water was added, extracted at 97 ° C. for 8 hours, filtered, and the crude stock was extracted. Glucosamine, MSM, and chitosan oligosaccharides were mixed with the extract at 85 ° C, homogenized by mixing honey, fructose, and caramel, and the mixture was sterilized for 15 seconds in a HTST (high temperature sterilizer) calibrated to 95 ° C. A nervous breakdown improved natural beverage composition was prepared.
상기된 바와 같은 방법으로 갱년기 우울증 및 신경쇠약 개선 음료 조성물을 제조하는데 사용되는 각각의 성분 및 그 함량은 다음과 같다.Each of the ingredients and their contents used to prepare the menopausal depression and nervous breakdown beverage composition in the same manner as described above are as follows.
녹용 추출액 : 2.4중량Deer Antler Extract: 2.4 weight
지황 추출액: 2.5중량Foxglove Extract: 2.5 weight
오미자 추출액: 2.4중량Schizandra chinensis extract: 2.4 weight
맥문동 추출액: 10.2중량Macmundong Extract: 10.2 weight
당귀 추출액: 10.2중량Angelica extract: 10.2 weight
복령 추출액: 1.02중량Bokryeong Extract: 1.02 weight
작약 추출액: 10.2중량Peony extract: 10.2 weight
대추 추출액:10.2중량Jujube extract: 10.2 weight
감초 추출액: 5.1중량Licorice extract: 5.1 weight
진피 추출액: 5.1중량Dermis Extract: 5.1 Weight
법제 산조인 추출액: 5.1중량Legal Sanjoin Extract: 5.1
천궁 추출액: 5.1중량Cheongung Extract: 5.1
치자 추출액: 4.1중량Gardenia extract: 4.1 weight
글루코사민: 0.63중량Glucosamine: 0.63 weight
MSM: 0.63중량MSM: 0.63 weight
키토산올리고당: 0.25중량Chitosan oligosaccharides: 0.25 weight
꿀: 3.7 중량Honey: 3.7 weight
액상과당: 3.7중량Liquid fructose: 3.7 weight
카라멜: 0.25중량Caramel: 0.25 weight
상기 제조된 우울증 및 신경쇠약 개선 천연 음료 조성물을 50대 성인 남, 여 각각 10명을 1개조로 하여 60명을 대상으로 우울증 및 신경쇠약의 일반적인 증상을 항목으로 하여 조성물의 효능을 시험하였다. 음용 방법은 아침에 식전 1시간과 취침 1시간전 일일 2회씩 15일간 음용하도록 한 후에 갱년기 우울증 및 신경쇠약 개선 효과에 대한 관능 검사를 실시하였다.The efficacy of the composition was tested for the general symptoms of depression and nervous breakdown in 60 adults and 10 males and 50 females in the depression and nervous breakdown improvement natural beverage composition prepared above. Drinking method was to drink twice a day for 1 hour before meals and 1 hour before bed in the morning for 15 days, and then sensory tests for improvement of menopausal depression and nervous breakdown.
검사시의 점수는 다음과 같이 부여하였다.The score at the time of examination was given as follows.
1...... 전혀 효과가 없다.1 ...... No effect at all.
2...... 별로 효과가 없다.2 ...... Not very effective.
3...... 보통이다.3 ...... Normal.
4...... 조금 효과가 있다.4 ...... a little effective.
5...... 아주 효과가 있다.5 ...... Very effective.
참조예 1Reference Example 1
음료 조성물에 함유되는 양을 하기 나타낸 바와 같이 함을 제외하고는 실시예 1과 유사한 방법으로 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 제조하였다.A menopausal depression and nervous breakdown improvement natural beverage composition was prepared in a similar manner as in Example 1 except that the amount contained in the beverage composition was as shown below.
녹용 추출액 : 2.4중량Deer Antler Extract: 2.4 weight
지황 추출액: 2.5중량Foxglove Extract: 2.5 weight
오미자 추출액: 2.4중량Schizandra chinensis extract: 2.4 weight
맥문동 추출액: 10.2중량Macmundong Extract: 10.2 weight
당귀 추출액: 10.2중량Angelica extract: 10.2 weight
복령 추출액: 10.2중량Bokryeong Extract: 10.2 weight
작약 추출액: 10.2중량Peony extract: 10.2 weight
대추 추출액: 10.2중량Jujube extract: 10.2 weight
감초 추출액: 5.1중량Licorice extract: 5.1 weight
진피 추출액: 5.1중량Dermis Extract: 5.1 Weight
법제 산조인 추출액: 5.1중량Legal Sanjoin Extract: 5.1
천궁 추출액: 5.1중량Cheongung Extract: 5.1
치자 추출액: 4.1중량Gardenia extract: 4.1 weight
생강 추출액: 8.1중량Ginger Extract: 8.1
글루코사민: 0.32중량Glucosamine: 0.32 weight
MSM: 0.32중량MSM: 0.32 weight
키토산올리고당: 0.15중량Chitosan oligosaccharides: 0.15 weight
꿀: 4.16중량Honey: 4.16 weights
액상과당: 4.16중량Liquid fructose: 4.16 weights
카라멜: 0.25중량Caramel: 0.25 weight
상기 제조된 참조 목적의 천연 음료 조성물을 실시예 1에서와 동일한 방법으로 갱년기 우울증 및 신경쇠약 개선 효과에 대한 관능 검사를 실시하였다.In the same manner as in Example 1, the prepared natural beverage composition for reference purpose was subjected to sensory tests for the effect of improving menopausal depression and nervous breakdown.
참조예 2Reference Example 2
실시예 1의 천연 약재의 배합 비율을 달리한 후 제조방법은 동일하게 하여 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 제조하였다.After varying the blending ratio of the natural medicine of Example 1 was prepared in the same manner to prepare menopausal depression and nervous breakdown natural beverage composition.
녹용 추출액 : 1.0중량Deer Antler Extract: 1.0 weight
지황 추출액: 5.0중량Foxglove Extract: 5.0 wt.%
오미자 추출액: 5.0중량Schizandra extract: 5.0 weight
당귀 추출액: 6중량Angelica Extract: 6 weights
맥문동 추출액: 6중량Macmundong Extract: 6 weights
복령 추출액: 12중량Refuge Extract: 12 weights
작약 추출액: 10중량Peony extract: 10 weight
대추 추출액:12중량Jujube extract: 12 weight
감초 추출액: 10중량Licorice extract: 10 weight
진피 추출액: 8중량Dermis Extract: 8 Weights
법제 산조인 추출액: 5.1중량Legal Sanjoin Extract: 5.1
천궁 추출액: 8중량Cheongung Extract: 8 weights
치자 추출액: 6중량Gardenia extract: 6 weights
생강 추출액: 3중량Ginger Extract: 3 weights
글루코사민: 0.6중량Glucosamine: 0.6 weight
MSM: 0.6중량MSM: 0.6 Weight
키토산올리고당: 0.1중량Chitosan oligosaccharides: 0.1 weight
꿀: 2.7 중량Honey: 2.7 weight
액상과당: 2.7중량Liquid fructose: 2.7 weights
카라멜: 0.3중량Caramel: 0.3 weight
상기 제조된 참조 목적의 갱년기 우울증 및 신경쇠약 개선 천연 음료 조성물을 실시예 1에서와 동일한 방법으로 갱년기 우울증 및 신경쇠약 개선 효과에 대한 관능 검사를 실시하였다.The sensory test for menopausal depression and nervous breakdown improvement was performed in the same manner as in Example 1 for the prepared menopausal depression and nervous breakdown improvement.
참조예 3Reference Example 3
유효성분을 첨가하지 않음을 제외하고는 실시예 1에서와 유사한 방법으로 천연음료를 제조하였다.A natural beverage was prepared in a similar manner as in Example 1 except that no active ingredient was added.
녹용 추출액 : 2.4중량Deer Antler Extract: 2.4 weight
지황 추출액: 2.5중량Foxglove Extract: 2.5 weight
오미자 추출액: 2.4중량Schizandra chinensis extract: 2.4 weight
맥문동 추출액: 10.2중량Macmundong Extract: 10.2 weight
당귀 추출액: 10.2중량Angelica extract: 10.2 weight
복령 추출액: 10.2중량Bokryeong Extract: 10.2 weight
작약 추출액: 10.2중량Peony extract: 10.2 weight
대추 추출액: 10.2중량Jujube extract: 10.2 weight
감초 추출액: 5.73중량Licorice Extract: 5.73 Weight
진피 추출액: 5.73중량Dermis Extract: 5.73 Weight
법제 산조인 추출액: 5.1중량Legal Sanjoin Extract: 5.1
천궁 추출액: 5.26중량Cheongung Extract: 5.26
치자 추출액: 4.1중량Gardenia extract: 4.1 weight
생강 추출액: 8.1중량Ginger Extract: 8.1
꿀: 3.7 중량Honey: 3.7 weight
액상과당: 3.7중량Liquid fructose: 3.7 weight
카라멜: 0.25중량Caramel: 0.25 weight
상기 제조된 음료 조성물을 실시예 1에서와 동일한 방법으로 갱년기 우울증및 신경쇠약 개선 효과에 대한 관능 검사를 실시하였다.In the same manner as in Example 1, the beverage composition prepared above was subjected to a sensory test for improving menopausal depression and nervous breakdown.
비교예Comparative example
현재 시중에서 시판되고 있는 갱년기 우울증 및 신경쇠약 개선 음료가 없고, 단지 의약품으로 판매되고 있는 제품밖에 없어 의약품의 경우 본 발명의 제품과 비교 대상이 될 수 없어서, 본 발명의 제품과 유사한 조성을 가진(한약재에 한하며 기능성을 갖는 성분은 첨가되지 않은 유사 제품) 시판 제품을 종래의 음료 조성물(1) 및 음료 조성물(2)을 입수하여 실시예 1에서와 동일한 패널 관능 검사 및 효능 검사를 수행하고자 비교 시험하였다.There are no menopausal depression and neurodebilitating beverages currently on the market, and only products that are sold as medicines can not be compared with the products of the present invention. Similar products without functional ingredients) commercial products were compared and tested to obtain the same beverage composition (1) and beverage composition (2) and perform the same panel sensory test and efficacy test as in Example 1 .
결과result
상기 실험에 의한 데이터에서 알 수 있는 바와 같이, 본 발명의 음료 조성물은 아주 우수한 갱년기 우울증 및 신경쇠약 개선 효과를 나타내고 있으며, 또한 본 발명 음료 조성물의 성분의 조성범위를 벗어난 참조 목적의 음료 조성물 및 종래의 음료 조성물에 비해 현저하게 우수한 효과를 나타내고 있음을 알 수 있다.As can be seen from the data of the above experiments, the beverage composition of the present invention exhibits a very good menopausal depression and neurodebilitating effect, and also the beverage composition for reference purposes and the prior art which is outside the composition range of the components of the beverage composition of the present invention. It can be seen that it shows a remarkably excellent effect compared to the beverage composition of.
본 발명은 40대 후반의 폐경기 여성 또는 50대 남성에게서 흔히 볼 수 있는신경쇠약과 정신적 불안정, 우울증 및 우울증에 따르는 수면장애, 불안초조등 뇌기능 저하에 따른 정신적, 신체적 노화를 개선하는 효과가 있는 음료 조성물 및 이의 제조방법을 제공하고 있다.The present invention has an effect of improving the mental and physical aging due to the brain function, such as nervous breakdown and mental instability, depression and depression, anxiety anxiety that is common in menopausal women in the late 40s or men in their 50s Beverage compositions and methods for preparing the same are provided.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000022289A KR100363999B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving climacteric melancholia and nervous debility and method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000022289A KR100363999B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving climacteric melancholia and nervous debility and method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010097871A true KR20010097871A (en) | 2001-11-08 |
KR100363999B1 KR100363999B1 (en) | 2002-12-12 |
Family
ID=19667108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000022289A KR100363999B1 (en) | 2000-04-26 | 2000-04-26 | Beverage composition for improving climacteric melancholia and nervous debility and method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100363999B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040034761A (en) * | 2002-10-15 | 2004-04-29 | (주)바이오지노피아 | Process for Preparing an Energy and Health-promoting Beverage |
KR100519720B1 (en) * | 2002-05-09 | 2005-10-10 | 한국원자력연구소 | A propolis-containing mixture reducing damages induced by reactive oxygen and radiation and enhancing immune activity, and its preparation |
KR100538059B1 (en) * | 2002-08-27 | 2005-12-20 | 김구환 | Manufacturing method of stress-relieving foods containing red ginseng, cheonma, and raw sulfur juice |
KR100692402B1 (en) * | 2005-07-26 | 2007-03-09 | 건국대학교 산학협력단 | A pharmaceutical composition comprising the extract of gardenia for treating or preventing depression disease |
CN105639339A (en) * | 2015-12-29 | 2016-06-08 | 珠海市金隆生物科技有限公司 | Fatigue-resistance and immunity-enhancement chitosan oligosaccharide beverage and preparation method thereof |
WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
-
2000
- 2000-04-26 KR KR1020000022289A patent/KR100363999B1/en not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100519720B1 (en) * | 2002-05-09 | 2005-10-10 | 한국원자력연구소 | A propolis-containing mixture reducing damages induced by reactive oxygen and radiation and enhancing immune activity, and its preparation |
KR100538059B1 (en) * | 2002-08-27 | 2005-12-20 | 김구환 | Manufacturing method of stress-relieving foods containing red ginseng, cheonma, and raw sulfur juice |
KR20040034761A (en) * | 2002-10-15 | 2004-04-29 | (주)바이오지노피아 | Process for Preparing an Energy and Health-promoting Beverage |
KR100692402B1 (en) * | 2005-07-26 | 2007-03-09 | 건국대학교 산학협력단 | A pharmaceutical composition comprising the extract of gardenia for treating or preventing depression disease |
WO2016129902A1 (en) * | 2015-02-13 | 2016-08-18 | (주)아모레퍼시픽 | Composition for preventing, alleviating or treating burnout syndrome |
CN105639339A (en) * | 2015-12-29 | 2016-06-08 | 珠海市金隆生物科技有限公司 | Fatigue-resistance and immunity-enhancement chitosan oligosaccharide beverage and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100363999B1 (en) | 2002-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI478709B (en) | A useful oral or enteral composition for the recovery of bodily functions | |
CN101248873A (en) | Drinking food product with sight protection function | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
CN111616232A (en) | Children milk powder for promoting bone growth and preparation method thereof | |
WO2022016774A1 (en) | Composition beneficial for regulating intestinal tract, promoting digestion and improving constipation, and preparation method therefor | |
CN111227261A (en) | Prebiotic composition and application thereof | |
CN103190483A (en) | Children growth promotion milk tea | |
TW201713330A (en) | Composition for suppressing muscular fatty change | |
KR100364000B1 (en) | Sports beverage composition and method thereof | |
KR100363999B1 (en) | Beverage composition for improving climacteric melancholia and nervous debility and method thereof | |
KR100363998B1 (en) | Beverage composition for improving degenerative arthritis and method thereof | |
BR112013009150B1 (en) | LIQUID COMPOSITION, USE OF FAT, PROTEIN, DIGESIBLE CARBOHYDRATES AND FRUITS AND LIQUID COMPOSITION PREPARATION METHOD | |
JP2010083858A (en) | Nutrient suitable for improvement of symptom or nutritional condition of cancer patient | |
CN101129956B (en) | Traditional Chinese medicine for treating rickets | |
CN110559389A (en) | traditional Chinese medicine wine for treating hyperuricemia, gout and rheumatism and preparation method thereof | |
US20060210606A1 (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
CN114916631A (en) | Ultrahigh-purity octacosanol-flavone composite deuterium-depleted water combined and co-refined high-energy beverage and preparation method thereof | |
CN114617267A (en) | Reinforced composite bone peptide and preparation method and application thereof | |
CN101744945B (en) | Oral liquid for adjusting gastrointestinal function | |
CN114343180A (en) | A series of compositions with effects of clearing hollow viscera and removing toxic substance, and its application | |
CN107439866A (en) | Matrimony vine chickpea plant nutrients beverage and its preparation technology | |
KR101908850B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Anti-Obesity and the Method of Making the Same | |
CN103763944A (en) | Dietetic multi-component system | |
RU2680389C1 (en) | Method of correction of violations of metabolic processes in connective tissue | |
CN110384234A (en) | A kind of raising spacefarer body function compound formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20051128 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |